NCT02696941View on ClinicalTrials.gov

SGLT2 Inhibitors and Metformin on Metabolism and Non-Alcoholic SteatoHepatitis

PHASE1CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

February 29, 2016

Primary Completion Date

April 1, 2018

Study Completion Date

April 1, 2018

Conditions
Non-alcoholic Fatty Liver Disease
Interventions
DRUG

Metformin

Metformin 500mg once daily and titrated weekly to a dose of 1000mg twice daily for 3 months

DRUG

SGLT2 inhibitor

SGLT2 inhibitor has been recommended to be started as part of routine clinical care

Trial Locations (1)

Unknown

University of Oxford, Oxford

All Listed Sponsors
lead

University of Oxford

OTHER

NCT02696941 - SGLT2 Inhibitors and Metformin on Metabolism and Non-Alcoholic SteatoHepatitis | Biotech Hunter | Biotech Hunter